TouchIMMUNOLOGY caught up with Philippe Bégin (CHU Sainte-Justine, Montréal, Canada) to discuss the PEPITES trial results, investigating epicutaneous immunotherapy for peanut allergy in children.
The abstract entitled ‘Reduction in Severity Following 12 Months of Epicutaneous Immunotherapy for Peanut Allergy‘ (ABSTRACT NUMBER: 342) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions:
1. What are the goals of peanut allergy immunotherapy, in terms of clinical endpoints and patient/caregiver-reported outcomes? (0:14)
2. What did the PEPITES trial teach us about the clinical utility of epicutaneous immunotherapy for peanut allergy in children? (1:39)
3. What were the aims, design and findings of this study, and what is their significance for clinical practice? (3:15)
Disclosures: Philippe Bégin is the clinical trial investigator for DBV technology products.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
